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Abstract
Preoperative chemoradiation therapy (CRT) may induce downstaging in rectal cancer (RC). Short-course radiation therapy (SC-
RT) with immediate surgery does not cause substantial downstaging. However, the TNM classification adds the “y” prefix in both
groups to indicate possible treatment effects.We aim to compare stage-specific survival in these patients. RC patients treated with
surgery only, preoperative SC-RT followed by surgery within 10 days, or preoperative CRT, and diagnosed between 2008 and
2014 were included in this population-based study. Clinicopathological and outcome characteristics were analyzed. The study
included 11,925 patients. Large discrepancies existed between clinical and pathological stages after surgery only. Surgery-only
patients were older withmore comorbidities comparedwith SC-RTand CRTand hadworse 5-year survival (64%, 76%, and 74%,
respectively; p < 0.001). Five-year survival for stage I was similar after CRT and SC-RT (85% vs. 85%; p = 0.167) and compa-
rable between CRT-treated patients with stage I and those reaching a pathological complete response (pCR; 85% vs. 89%; p =
0.113). CRTwas independently associated with worse overall survival comparedwith SC-RT for stage II (HR 1.57 [95%CI 1.27–
1.95]; p < 0.001) and stage III (HR 1.43 [95%CI 1.23–1.70]; p < 0.001). Stage I disease after CRT has an excellent prognosis,
comparable with pCR and with same-stage SC-RT-treated patients without regression. Stage II or III after CRT has worse
prognosis than after SC-RT with immediate surgery. TNM should take the impact of preoperative therapy type on stage-
specific survival into account. In addition, clinical stage was a poor predictor of pathological stage.
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Introduction
The standard of care for rectal cancer (RC) patients is total
mesorectal excision (TME) with or without preoperative
therapy depending on clinical stage. For patients with locally
advanced RC, preoperative treatment consists of chemoradia-
tion therapy (CRT) intended to reduce local recurrence rates
and to facilitate radical surgery by inducing tumor regression
and possible downstaging [1, 2]. Significant tumor and nodal
downstaging is reported in patients treated with CRT and de-
pends on factors such as tumor type, clinical stage, and inter-
val between radiation therapy and surgery [3–7].
Downstaging is associated with an improved prognosis, espe-
cially in 8–24% of patients with a pathological complete re-
sponse (pCR) [1, 6, 8, 9]. The TNM staging system [10, 11]
recommends adding the prefix “y” to the TNM stage after
preoperative therapy to indicate that a tumor may have under-
gone treatment-induced response or regression.
Especially in Western European countries, patients may
also undergo preoperative short-course radiation therapy
(SC-RT) followed by immediate surgery [12–15].
Randomized trials show a small downstaging effect in these
patients [13, 14], and according to the definitions of the TNM
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classification, the “y” prefix should be added. However,
downstaging does not occur after SC-RT if the overall treat-
ment time (i.e., interval between start of radiation therapy and
rectal resection) does not exceed 10 days [16]. The prognostic
significance of ypTNM stage for patients in these groups (with
vs. without possible downstaging) is still unclear. Due to the
differences in levels of downstaging between groups of pa-
tients treated either with preoperative SC-RT followed by im-
mediate surgery or with CRT [17], it may be hypothesized that
the prognostic implications of the “y” prefix depend on the
type of preoperative therapy received, which limits the prog-
nostic value of staging.
The purpose of this study is therefore to investigate on a
population level whether stage-specific overall survival is dif-
ferent between patients treated with either SC-RT followed by
surgery within 10 days after start of treatment (no tumor re-
gression expected; ypTNM by definition, but may reflect
pTNM) or preoperative long-course CRT (intended to induce
tumor regression; ypTNM) and to compare results with pa-
tients who underwent surgery only (pTNM).
Patients and methods
Study design and patient selection
A population-based approach was employed using data from
the nationwide Netherlands Cancer Registry (NCR). This in-
stitute collects data on all newly diagnosed cancer patients in
the Netherlands since 1989. The registration is primarily
based on notification by the Dutch national digital pathology
registry (PALGA). Patient and clinicopathological data are
routinely collected from medical records by specially trained
data managers. Tumor location and histology is registered
according to the ICD-O3 classification. Follow-up data and
vital status are retrieved by linkage to the nationwide popula-
tion registries network.
Patients with RC diagnosed between January 2008 and
December 2014 who underwent a surgical resection were se-
lected from the NCR. Clinicopathological characteristics and
overall survival (including TNM stage-specific survival) were
compared between patients treated with surgery only, preop-
erative SC-RT with an overall treatment time that did not
exceed 10 days, and preoperative long-course CRT. The max-
imum interval of 10 days between start of SC-RT and surgery
was chosen, since tumor regression is not likely to occur with-
in this timeframe [16]. For patients in the CRT group, an
interval of at least 63 days (duration of CRT + 4 weeks to
provide the opportunity for tumor regression) and no longer
than 182 days (6 months; arbitrary) was required.
Cases were excluded if the date of surgery was not available
or if there was presence of distant metastases at time of surgery
or missing data regarding distant metastases. The samewas true
for cases with histopathological tumor type other than adeno-
carcinoma, mucinous carcinoma, or signet ring cell carcinoma.
Other exclusion criteria were missing values for pathological T
or N categories and surgical procedures other than a low ante-
rior resection (LAR), Hartmann’s procedure, abdominoperineal
excision (APE), or intersphincteric resection.
Comorbidity was only registered in the NCR for one spe-
cific region in the Netherlands, covering 12% of the popula-
tion. A subgroup analysis of this data was performed.
Preoperative therapy
The prevailing RC clinical guideline [18] during the inclusion
period recommended preoperative SC-RT for primarily re-
sectable RC (with the exception of cT1N0 tumors) consisting
of 5 × 5 Gy followed by surgery within 1 week. Long-course
CRT consisting of 45–50 Gy given in 25 fractions of 1.8–
2.0 Gy per day with concurrent oral chemotherapy (capecita-
bine 825–1000 mg/m2 twice daily) and followed by surgery
within 4–6 weeks was indicated for locally advanced RC (i.e.,
patients with clinical N2 disease, cT4 tumors, or tumors with
suspected involvement of the mesorectal fascia on imaging).
Patients treated with surgery only either had cT1N0 disease or
were unfit or did not give consent to undergo preoperative
treatment.
Statistical analysis
All data was entered in a database and analyzed using IBM
SPSS Statistics for Windows, version 22.0, Armonk, NY:
IBM Corp. Categorical variables were analyzed using the χ2
test. Cumulative overall survival was analyzed using the
Kaplan-Meier method with log rank test. Univariable and
multivariable analyses were performed by entering all appli-
cable clinical and pathological factors in a Cox regression
model. A p value of < 0.05 was considered statistically signif-
icant whereas a p value of < 0.1 was taken to reflect a trend
towards significance.
Results
Patient selection
The initial search of the NCR database identified 19,737 pa-
tients. Figure 1 depicts the selection process, resulting in the
inclusion of a total of 11,925 patients (2590 with surgery only,
4534 with SC-RT, and 4801 with CRT).
Clinicopathological factors
Table 1 provides the clinical and pathological characteristics.
Median interval between start of SC-RT and surgery was
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Fig. 1 Flow diagram showing the
selection process. SC-RT, short-
course radiation therapy; CRT,
chemoradiation therapy; NOS,
not otherwise specified; pT,
pathological tumor category; pN,
pathological nodal category
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Table 1 Clinicopathological characteristics of patients treated with surgery only, SC-RT, and CRT
Total Surgery only SC-RT CRT p value
n % n % n % n %
Total 11,925 2590 4534 4801
Gender 0.092
Male 7610 63.8 1608 62.1 2899 63.9 3103 64.6 0.485a
Female 4315 36.2 982 37.9 1635 36.1 1698 35.4
Age at diagnosis < 0.001
0–44 342 2.9 48 1.9 89 2.0 205 4.3
45–59 2583 21.7 334 12.9 886 19.5 1363 28.4
60–74 6078 51.0 1171 45.2 2289 50.5 2618 54.5
75+ 2922 24.5 1037 40.0 1270 28.0 615 12.8
Clinical T category < 0.001
cT1 302 3.1 147 8.0 133 3.8 22 0.5
cT2 2656 26.9 800 43.7 1415 40.1 441 9.8
cT3 6070 61.4 783 42.8 1933 54.7 3354 74.2
cT4 852 8.6 99 5.4 52 1.5 701 15.5
Missing 2045 761 1001 283
Clinical N category < 0.001
cN0 5272 49.7 1824 80.7 2594 65.9 854 19.4
cN1 3284 31.0 348 15.4 1193 30.3 1743 39.6
cN2 2043 19.3 88 3.9 148 3.8 1807 41.0
Missing 1326 330 599 397
Clinical TNM stage < 0.001
Stage I 1879 20.2 789 45.2 989 30.3 109 2.3
Stage II 2117 22.7 519 29.8 930 28.5 686 15.5
Stage III 5327 57.1 436 25.0 1341 41.1 3602 82.2
Missing 2602 846 1274 482
Type of resection < 0.001
Sphincter savingb 8161 68.4 2152 83.1 3361 74.1 2648 55.2
Non-sphincter savingc 3764 31.6 438 16.9 1173 25.9 2153 44.8
Pathological T category < 0.001
(y)pT0 979 8.2 5 0.2 34 0.7 940 19.6
(y)pT1 1050 8.8 380 14.7 336 7.4 334 7.0
(y)pT2 4073 34.2 893 34.5 1852 40.8 1328 27.7
(y)pT3 5450 45.7 1206 46.6 2237 49.3 2007 41.8
(y)pT4 373 3.1 106 4.1 75 1.7 192 4.0
Pathological N category < 0.001
(y)pN0 8098 67.9 1775 68.5 2958 65.2 3365 70.1
(y)pN1 2632 22.1 568 21.9 1081 23.8 983 20.5
(y)pN2 1195 10.0 247 9.5 495 10.9 453 9.4
Pathological TNM stage < 0.001
Stage 0 895 7.5 4 0.2 25 0.6 866 18.0
Stage I 4070 34.1 1058 40.8 1705 37.6 1307 27.2
Stage II 3133 26.3 713 27.5 1228 27.1 1192 24.8
Stage III 3827 32.1 815 31.5 1576 34.8 1436 29.9
CRM involvementd < 0.020
Absent 9605 92.4 1981 91.6 3695 93.3 3929 92.0 0.018*
Present 788 7.6 181 8.4 264 6.7 343 8.0
Missing 1532 428 575 529
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8 days (range 0–10), and in the CRT group, the median inter-
val was 100 days (range 63–182). Patients in the surgery-only
group were older than those in the SC-RT group, who in turn
were older than the CRT-treated patients (age > 75 years; 40%,
28%, and 13% in the surgery-only, SC-RT, and CRT groups,
respectively; p < 0.001). Other factors that were significantly
associated with the type of preoperative treatment were cT
category, cN category, cTNM stage, type of resection, pT
category, pN category, pTNM stage, CRM involvement, his-
tological type, and presence of postoperative chemotherapy.
Patients in the CRT group showed ypT0 in 20% of cases and
had a reduced rate of (y)pT2 and (y)pT3 tumors compared
with those in the surgery-only and SC-RT groups
(p < 0.001). A pCR (ypT0N0) occurred in 18% of cases after
CRT.
A subgroup analysis of cases with available comorbidity
data (n = 1270) showed a higher rate of comorbidities in the
surgery-only group compared with both the SC-RT and CRT
groups with ≥ 2 comorbidities in 45%, 35%, and 25% of cases
for surgery only, SC-RT, and CRT, respectively (p < 0.001 for
surgery only vs. CRT; p = 0.006 for surgery only vs. SC-RT;
p = 0.003 for SC-RT vs. CRT).
Correlation between cTNM and (y)pTNM
The data showed substantial discrepancies between clini-
cal and pathological TNM stages (Table 2). Patients with
suspected LN on clinical imaging had histopathology
showing nodal disease in 57%, 49%, and 35% of cases
that were treated with surgery only, SC-RT, and CRT,
respectively (p < 0.001). Patients with clinical stage I dis-
ease had histopathological nodal involvement in 19%,
24%, and 13% after surgery only, SC-RT, and CRT, re-
spectively (p = 0.004). For patients with clinical stage II,
this was 26%, 30%, and 15%, respectively (p < 0.001). In
the CRT group, there was complete tumor regression in
30%, 19%, and 17% of cases for patients with clinical
stage I, II, and III disease, respectively (p < 0.001).
Table 2 Correlation between clinical and pathological stages
N = 9323a Clinical stage
Stage I Stage II Stage III
n % n % n %
Surgery only Pathological stage
Stage 0 2 0.3 1 0.2 0 0.0
Stage I 481 61.0 146 28.1 81 18.6
Stage II 154 19.5 237 45.7 108 24.8
Stage III 152 19.3 135 26.0 247 56.7
Total 789 100.0 519 100.0 436 100.0
SC-RT Pathological stage
Stage 0 15 1.5 1 0.1 4 0.3
Stage I 535 54.1 286 30.8 359 26.8
Stage II 199 20.1 368 39.6 320 23.9
Stage III 240 24.3 275 29.6 658 49.1
Total 989 100.0 930 100.0 1341 100.0
CRT Pathological stage
Stage 0 30 29.7 129 19.3 601 16.9
Stage I 40 39.6 205 30.7 898 25.3
Stage II 18 17.8 235 35.2 821 23.1
Stage III 13 12.9 99 14.8 1230 34.6
Total 101 100.0 668 100.0 3550 100.0
SC-RT short-course radiation therapy, CRT chemoradiation therapy
a Cases with missing values for clinical TNM stage were excluded (n =
2602)
Table 1 (continued)
Total Surgery only SC-RT CRT p value
n % n % n % n %
Histological type 0.009
Adenocarcinoma 11,049 92.7 2436 94.1 4208 92.8 4405 91.8 0.158*
Mucinous carcinoma 825 6.9 144 5.6 308 6.8 373 7.8
Signet ring cell carcinoma 51 0.4 10 0.4 18 0.4 23 0.5
Postoperative CTx 0.013
No 11,175 93.7 2395 92.5 4263 94.0 4517 94.1
Yes 750 6.3 195 7.5 271 6.0 284 5.9
SC-RT short-course radiation therapy, CRT chemoradiation therapy, CRM circumferential resection margin, CTx chemotherapy
a SC-RT vs. CRT
b Includes 6887 patients with low anterior resection, 1186 patients with Hartmann’s procedure, and 88 patients with intersphincteric resection
c Patients with abdominoperineal excision
d Circumferential resection margin (CRM) involvement was defined as tumor distance to the CRM ≤ 1 mm
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Table 3 Overall survival
Cumulative 5-year overall survival p valuea HR 95%CI
Overall 73%
Preoperative therapy < 0.001
SC-RT 76.3 0.147† 1.00 –
CRT 73.5 1.07 0.96–1.19
None (surgery only) 64.1 1.73 1.55–1.94
Gender < 0.001
Male 71.3 1.00 –
Female 76.0 0.77 0.70–0.85
Age at diagnosis < 0.001
0–44 85.2 1.00 –
45–59 82.0 1.18 0.81–1.72
60–74 76.9 1.76 1.23–2.52
75+ 56.1 4.10 2.87–5.87
Clinical T category < 0.001
cT1 75.0 1.00 –
cT2 78.7 0.99 0.70–1.39
cT3 73.1 1.36 0.98–1.89
cT4 61.0 2.15 1.51–3.05
Missing 71.2 1.52 1.09–2.12
Clinical N category 0.007
cN0 74.2 1.00 –
cN1 71.9 1.10 0.99–1.23
cN2 73.6 0.98 0.84–1.13
Missing 70.6 1.22 1.08–1.38
Clinical TNM stage < 0.001
Stage I 78.9 1.00 –
Stage II 72.0 1.46 1.23–1.73
Stage III 72.4 1.38 1.18–1.61
Missing 71.5 1.51 1.29–1.77
Type of resection 0.004
Sphincter saving 74.0 1.00 –
Non-sphincter saving 71.1 1.15 1.05–1.26
Pathological T category < 0.001
pT0 87.2 0.73 0.54–0.99
pT1 82.0 1.00 –
pT2 81.0 1.14 0.92–1.41
pT3 65.2 2.22 1.81–2.71
pT4 45.9 4.50 3.48–5.82
Pathological N category < 0.001
pN0 79.2 1.00 –
pN1 67.2 1.65 1.49–1.84
pN2 47.6 3.13 2.79–3.51
Pathological stage < 0.001
Stage 0 89.2 0.62 0.47–0.83
Stage I 83.3 1.00 –
Stage II 71.5 1.76 1.55–2.00
Stage III 60.9 2.61 2.32–2.93
Histological type < 0.001
Adenocarcinoma 73.9 1.00 –
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Survival analysis
Median follow-up was 28 months (range 0–84 months) and
1949 deaths were recorded (16.3%). Cumulative 5-year over-
all survival was 73% (Table 3). The surgery-only group
showed worse overall survival than the SC-RT and CRT
groups (64%, 76%, and 74% for surgery only, SC-RT, and
CRT, respectively; p < 0.001). However, there was no signif-
icant difference between patients treated with SC-RT vs. CRT
(p = 0.147).
Clinical stage before neoadjuvant therapy was significantly
associated with overall survival, although the hazard ratios are
lower than those for pathological stage, and in the study pop-
ulation, the hazard ratios do not consistently increase with
clinical stage in contrast to pathological stage, suggesting that
the prognostic value of clinical stage is limited (HR 1.00, HR
1.46, and HR 1.38 for clinical TNM stages I, II, and III, re-
spectively; and HR 0.62, HR 1.00, HR 1.76, and HR 2.61 for
pathological TNM stages 0, I, II, and III, respectively).
Figure 2a–c show stage-specific overall survival for pa-
tients with surgery only, SC-RT, and CRT. Survival was worst
in the surgery-only group (cumulative 5-year survival 77%,
63%, and 52% for pathological stages I, II, and III, respective-
ly; p ≤ 0.003 compared with SC-RT and CRT). SC-RT-treated
patients with pathological stage I disease had similar overall
survival as same-stage patients in the CRT group (cumulative
5-year survival 85% vs. 85%, respectively; p = 0.167). After
CRT overall survival was comparable in patients with patho-
logical stage I and those who reached a pCR (cumulative 5-
year survival 85% vs. 89% respectively; p = 0.113). The SC-
RT group showed better survival than the CRT group for
patients with pathological stage II (cumulative 5-year survival
77% vs. 68% for SC-RT vs. CRT, respectively; p = 0.002) and
stage III (cumulative 5-year survival 67% vs. 58% for SC-RT
vs. CRT, respectively; p < 0.001).
The multivariable analysis (Table 4) showed that CRTwas
independently associated with a higher mortality compared
with SC-RT in patients with pathological stage II (HR 1.57
[95%CI 1.27–1.95]; p < 0.001) and stage III (HR 1.43 [95%CI
1.23–1.70]; p < 0.001), but not in those with stage I (HR 0.99
[95%CI 0.77–1.27]; p = 0.146). The hazard ratio for patients
with surgery only was also increased compared with SC-RT
for patients with pathological stage II (HR 1.67 [95%CI 1.35–
2.08]; p < 0.001) and stage III (HR 1.60 [95%CI 1.36–1.87];
p < 0.001), but not stage I (HR 1.25 [95%CI 0.99–1.59]; p =
0.137).
Discussion
In this population-based study, using data from the
Netherlands Cancer Registry, long-term stage-specific surviv-
al data was analyzed from 11,925 RC patients who underwent
TME surgery with or without preoperative treatment
consisting of either SC-RTor CRT. Patients with downstaging
to pathological stage I disease after CRT had an excellent 5-
year overall survival which was similar as in SC-RT-treated
patients without downstaging (85%). For patients with patho-
logical stages II and III, survival was significantly worse after
CRT (68% and 58%) compared with SC-RT (77% and 67%).
In addition, clinical staging was a poor predictor of patholog-
ical stage based on the large discrepancies between clinical
and pathological stages in the surgery-only group.
In the study period, the national clinical guideline [18]
recommended preoperative SC-RTwith 5 × 5 Gy and surgery
within 1 week for primarily resectable RC (with the exception
of cT1N0 tumors) and long-course CRT consisting of 45–
50 Gy given in 25 fractions of 1.8–2.0 Gy per day with con-
current oral capecitabine for locally advanced RC (see
“Patients and methods” section for details). Patients treated
Table 3 (continued)
Cumulative 5-year overall survival p valuea HR 95%CI
Mucinous carcinoma 66.2 1.41 1.21–1.63
Signet ring cell carcinoma 21.9 4.17 2.74–6.35
CRM involvement < 0.001
Absent 75.0 1.00 –
Present 53.5 2.24 1.97–2.56
Missing 73.1 1.17 1.04–1.32
Postoperative CTx 0.007
No 72.7 1.00 –
Yes 77.4 0.78 0.65–0.93
SC-RT short-course radiation therapy, CRT chemoradiation therapy, CRM circumferential resection margin, CTx chemotherapy
a Log-rank test
† SC-RT vs. CRT
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Fig. 2 Overall survival for
patients treated with surgery only,
SC-RT, or CRT. a Pathological
stage I. b Pathological stage II. c
Pathological stage III. SC-RT,
short-course radiation therapy;
CRT, chemoradiation therapy
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with surgery only in this period either had cT1N0 disease or
were unfit or did not give consent to undergo the indicated
preoperative therapy. Indeed, patients in the surgery-only
group were found to be substantially older and had more co-
morbidity compared with both the SC-RT and CRT groups.
These patients were therefore considered to be unsuitable as a
control population in the current study.
On the other hand, the comparison of the SC-RT- and CRT-
treated patients in this study yields some interesting results.
Although some small downstaging effect on T-stage and nodal
downstaging have been reported in randomized trials after
SC-RT with immediate surgery [13, 14], the SC-RT-treated
patients in the current study all had an overall treatment time
not exceeding 10 days, and evidence from a large randomized
controlled trial showed that tumor and nodal downstaging
do not occur in this short timeframe [16]. Furthermore,
stage-specific 10-year overall survival was shown to be simi-
lar in randomized patients with preoperative SC-RT and those
Table 4 Multivariable Cox regression analysis for overall survival of patients with pathological TNM stages I–III
(y)pTNM stage I (y)pTNM stage II (y)pTNM stage III
HR 95%CI p value HR 95%CI p value HR 95%CI p value
Preoperative therapy 0.146 < 0.001 < 0.001
SC-RT 1.00 – 1.00 – 1.00 –
CRT 0.99 0.77–1.27 1.57 1.27–1.95 1.43 1.23–1.70
None (surgery only) 1.25 0.99–1.59 1.67 1.35–2.08 1.60 1.36–1.87
Gender < 0.001 0.007 < 0.001
Male 1.00 – 1.00 – 1.00 –
Female 0.61 0.49–0.76 0.78 0.65–0.94 0.77 0.67–0.89
Age at diagnosis < 0.001 < 0.001 < 0.001
0–44 0.81 0.24–2.71 0.80 0.37–1.74 0.97 0.61–1.53
45–59 1.00 – 1.00 – 1.00 –
60–74 2.99 1.95–4.59 1.23 0.94–1.61 1.35 1.12–1.63
75+ 7.88 5.14–12.10 2.89 2.20–3.79 2.81 2.29–3.45
Type of resection 0.147 0.025 0.002
Sphincter saving 1.00 – 1.00 – 1.00 –
Non-sphincter saving 1.17 0.95–1.45 1.24 1.03–1.49 1.25 1.09–1.44
pT category 0.588 < 0.001 < 0.001
pT0 – – – – 1.48 0.75–2.90
pT1 1.00 – – – 1.00 –
pT2 0.93 0.73–1.20 – – 1.20 0.75–1.92
pT3 – – 1.00 – 1.91 1.22–3.00
pT4 – – 1.79 1.32–2.42 3.03 1.85–4.97
pN category < 0.001
pN1 – – – – 1.00 –
pN2 – – – – 1.88 1.65–2.15
Histological type 0.031 0.176 0.022
Adenocarcinoma 1.00 – 1.00 – 1.00 –
Mucinous carcinoma 0.78 0.48–1.25 1.15 0.87–1.52 1.16 0.95–1.41
Signet ring cell carcinoma 11.29 1.56–81.70 2.57 0.82–8.07 1.85 1.13–3.03
CRM involvement 0.040 0.001 < 0.001
Absent 1.00 – 1.00 – 1.00 –
Present 1.76 1.14–2.71 1.61 1.25–2.07 1.54 1.29–1.84
Missing 1.03 0.80–1.33 1.23 0.98–1.54 1.15 0.96–1.38
Postoperative CTx 0.474 0.008 < 0.001
No 1.00 – 1.00 – 1.00 –
Yes 0.60 0.15–2.43 0.30 0.13–0.73 0.56 0.46–0.69
p pathological, SC-RT short-course radiation therapy,CRTchemoradiation therapy, AC adenocarcinoma,MCmucinous carcinoma, SRCC signet ring cell
carcinoma, CRM circumferential resection margin, CTx chemotherapy
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with surgery only or surgery with selective postoperative CRT
[12–14]. This lack of downstaging and absence of a survival
difference suggest that the SC-RT-treated patients in the cur-
rent study may be regarded best as pTNM rather than ypTNM
[19].
The observed difference in stage-specific survival between
patients treated with CRT (substantial downstaging) and SC-
RT (no downstaging) was substantial and highly significant,
and the effect was independent of several known possible
confounders. However, selection bias may be a concern when
interpreting these results. The inherently higher levels of
treatment-induced toxicity caused by CRT may motivate cli-
nicians to withhold this treatment in elderly patients with co-
morbidity, whereas the same comorbidity level would not pre-
clude a treatment with much less toxic SC-RT. Unfortunately,
comorbidity data was not available in the majority of patients
and the results of the multivariable analysis could therefore
not be corrected for this confounder. However, the subset
analysis of patients with available comorbidity data showed
that comorbidity levels were higher in the SC-RT than in the
CRT group. As a consequence, the SC-RT group as a whole
may be expected to show a bias towards a worse prognosis
compared with the CRT group. However, the multivariable
analysis showed the direct opposite with a better prognosis
in the SC-RT group for patients with stage II and III disease.
The observed survival differences may therefore be expected
to be even larger if the results could be adjusted for
comorbidity.
The introduction of preoperative CRT for RC which
has resulted in tumor downstaging in a substantial pro-
portion of patients has not resulted in improved survival
compared with selective postoperative CRT [20]. The
stage-specific outcome differences between the groups
in this study are therefore not based on a therapeutic
effect of the preoperative treatment, but are probably
best explained by pathological stage migration. Patients
with nodal disease may undergo sterilization of involved
LN after CRT resulting in classification as pathological
stage I or II disease instead of stage III.
Patients with downstaging to ypTNM stage I reflect a
selection of treatment-sensitive tumors. The excellent
survival observed in these patients, which is similar to
SC-RT-treated pTNM stage I patients, suggests that po-
tential occult disease or metastases also undergo sub-
stantial regression in patients with treatment-sensitive
tumors. As a consequence, the observed mortality will
increase in the ypTNM stage III patients with residual
nodal metastases, since this group constitutes a selection
of patients with treatment-resistant tumors. Furthermore,
mortality can also be expected to increase in the
ypTNM stage II group after CRT. This group is
enriched with cases that had nodal disease at baseline,
with higher risk of occult residual disease but with only
intermediate regression to therapy, and this may corre-
spond to intermediate regression of potential occult re-
sidual disease as well. This effect, called “the reverse of
the Will Rogers phenomenon,” has been described be-
fore with data from the German CAO/ARO/AIO-94 tri-
al, showing that patients with pathological stage II dis-
ease after preoperative CRT had worse overall survival
than same-stage patients from the control arm treated
with selective postoperative CRT [21].
A limitation to the current study is that it is not
possible to determine the exact rate of stage migration
in CRT-treated patients, since clinical staging (especially
cN category) is notoriously unreliable [22–25]. Indeed,
data from this study showed large discrepancies between
clinical and pathological stages in the surgery-only
group (no downstaging by definition) with pathological-
ly confirmed LN metastases in only 57% of patients
with clinical stage III disease. The differences between
clinical and pathological stages in the surgery-only and
SC-RT groups and at least a part of the variation ob-
served in the CRT group are therefore probably related
to the imprecision of clinical staging and not to actual
stage migration. This imprecision is reflected in the rel-
atively limited prognostic value of clinical stage
(cTNM) compared with definitive pathological stage
((y)pTNM) observed in this study. Another important
restriction is the lack of an adequate pTNM control
group, due to the high level of selection bias in patients
treated with surgery only.
Furthermore, precise details regarding chemotherapy
types and doses received were not available for individ-
ual patients, since the national cancer registry does not
document this information. It is likely that a part of
individual patients in the long-course CRT group re-
ceived doses that are not equal to the recommended
dose due to toxicity issues. In addition, it is possible
that some patients in this group received additional che-
motherapeutic agents besides capecitabine as part of a
clinical trial. Unfortunately, the impact of these minor
treatment variations on the results of this study cannot
be ascertained.
In conclusion, this population-based study provides
evidence that pathological stage I after preoperative
CRT for RC is associated with an excellent prognosis,
which is comparable with reaching a pCR and similar to
same-stage SC-RT-treated patients without tumor regres-
sion. In patients with pathological stage II and III dis-
ease after CRT, the prognosis is worse than after SC-RT
with immediate surgery. These results contain important
prognostic information for individual patients and phy-
sicians and may have consequences for predictive
models. Staging systems, such as TNM, should there-
fore take stage-specific survival differences between
Virchows Arch
patients treated with different preoperative therapy regi-
mens into account.
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